## John A Heit

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5033356/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination. JAMA Internal Medicine, 2022, 182, 80.	5.1	11
2	Multiâ€phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. Journal of Thrombosis and Haemostasis, 2022, 20, 1331-1349.	3.8	12
3	Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood, 2019, 134, 1645-1657.	1.4	162
4	Coronary Embolus. JACC: Cardiovascular Interventions, 2018, 11, 172-180.	2.9	113
5	ls Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study. American Journal of Medicine, 2018, 131, 307-316.e2.	1.5	40
6	Venous Thromboembolism (VTE) Incidence and VTE-Associated Survival among Olmsted County Residents of Local Nursing Homes. Thrombosis and Haemostasis, 2018, 118, 1316-1328.	3.4	6
7	Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. Blood, 2017, 130, 109-114.	1.4	90
8	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making. Journal of Women's Health, 2017, 26, 1350-1355.	3.3	0
9	Reasons for the persistent incidence of venous thromboembolism. Thrombosis and Haemostasis, 2017, 117, 390-400.	3.4	89
10	Identification of Genetic Interaction with Risk Factors Using a Time-To-Event Model. International Journal of Environmental Research and Public Health, 2017, 14, 1228.	2.6	1
11	Identification of unique venous thromboembolism-susceptibility variants in African-Americans. Thrombosis and Haemostasis, 2017, 117, 758-768.	3.4	35
12	Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiological Genomics, 2016, 48, 33-41.	2.3	23
13	Periprocedural Anticoagulation Management of Patients with Thrombophilia. American Journal of Medicine, 2016, 129, 986-992.	1.5	4
14	The epidemiology of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 3-14.	2.1	749
15	Risk factors for incident venous thromboembolism in active cancer patients: A population based case–control study. Thrombosis Research, 2016, 139, 29-37.	1.7	58
16	Direct Medical Costs Attributable to Cancer-Associated Venous Thromboembolism: A Population-Based Longitudinal Study. American Journal of Medicine, 2016, 129, 1000.e15-1000.e25.	1.5	28
17	Longitudinal effects of menopausal hormone treatments on platelet characteristics and cell-derived microvesicles. Platelets, 2016, 27, 32-42.	2.3	27
18	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	6.2	101

**Ј**ОНN Α ΗΕΙΤ

#	Article	IF	CITATIONS
19	Prevalence and risk factors for post thrombotic syndrome after deep vein thrombosis in children: A cohort study. Thrombosis Research, 2015, 135, 347-351.	1.7	25
20	Direct medical costs attributable to venous thromboembolism among persons hospitalized for major operation: A population-based longitudinal study. Surgery, 2015, 157, 423-431.	1.9	26
21	Epidemiology of venous thromboembolism. Nature Reviews Cardiology, 2015, 12, 464-474.	13.7	783
22	Risk of site-specific cancer in incident venous thromboembolism: A population-based study. Thrombosis Research, 2015, 135, 472-478.	1.7	61
23	Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case–control study. Thrombosis Research, 2015, 135, 1110-1116.	1.7	16
24	The association of copy number variation and percent mammographic density. BMC Research Notes, 2015, 8, 297.	1.4	2
25	Predictors of Venous Thromboembolism Recurrence, Adjusted for Treatments and Interim Exposures: A Population-based Case-cohort Study. Thrombosis Research, 2015, 136, 298-307.	1.7	40
26	Abstract 303: Risk Factors for Venous Thromboembolism (VTE) among Patients with Neurologic Disease and Leg Paresis: A Population-based Case-control Study Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	0
27	Venous Gangrene and Intravascular Coagulation and Fibrinolysis in a Patient Treated with Rivaroxaban. American Journal of Medicine, 2014, 127, e7-e8.	1.5	4
28	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nature Communications, 2014, 5, 5303.	12.8	109
29	Are myocardial infarction and venous thromboembolism associated? Population-based case–control and cohort studies. Thrombosis Research, 2014, 134, 593-598.	1.7	14
30	Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood, 2014, 123, 3972-3978.	1.4	167
31	Rethinking Guidelines for VTE Risk Among Nursing Home Residents. Chest, 2014, 146, 412-421.	0.8	9
32	A Genomeâ€Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. Genetic Epidemiology, 2013, 37, 512-521.	1.3	99
33	The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. Blood, 2012, 119, 2392-2400.	1.4	56
34	Prevention of VTE in Nonorthopedic Surgical Patients. Chest, 2012, 141, e227S-e277S.	0.8	1,819
35	Predicting the risk of venous thromboembolism recurrence. American Journal of Hematology, 2012, 87, S63-7.	4.1	82
36	Trends in the Incidence of Venous Thromboembolism Adjusted for Body Mass Index (BMI) Blood, 2012, 120, 2256-2256.	1.4	0

Јони А Неіт

#	Article	IF	CITATIONS
37	Single Nucleotide Polymorphisms (SNPs) Associated with Pulmonary Embolism (PE): A Genome-Wide Association Study (GWAS). Blood, 2012, 120, 1148-1148.	1.4	0
38	Thrombophilia Effect On Periprocedural Thromboembolism and Bleeding in Chronically Anticoagulated Patients. Blood, 2012, 120, 3404-3404.	1.4	0
39	Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood, 2011, 118, 4992-4999.	1.4	67
40	Association of Gene-Environment Interactions with Venous Thromboembolism (VTE): A Merged/Imputed Genome-Wide Scan/Candidate-Gene Case-Control Study. Blood, 2011, 118, 2295-2295.	1.4	1
41	HIT Antibody Seropositivity and Thromboembolic Events After Cardiac Surgery. Blood, 2011, 118, 1159-1159.	1.4	0
42	Identification of Patients At High Risk for Recurrent Venous Thromboembolism by Whole Blood Gene Expression Analysis. Blood, 2011, 118, 2305-2305.	1.4	8
43	Impact of Interim Hospitalizations on Risk of Venous Thromboembolism (VTE) Recurrence: A Nested Case-Cohort Study. Blood, 2011, 118, 1241-1241.	1.4	0
44	Association of Gene-Gene Interactions with Venous Thromboembolism (VTE): A Merged/Imputed Genome-Wide Scan/Candidate-Gene Case-Control Study. Blood, 2011, 118, 1242-1242.	1.4	0
45	Detection of Continuous Flow Left Ventricular Assist Device -Associated Acquired Von Willebrand Factor (VWF) Abnormality by An Automated Immunoturbidimetric VWF Activity Assay. Blood, 2011, 118, 2273-2273.	1.4	0
46	Identification of Venous Thromboembolism (VTE)-Associated Novel Variants in the ABO Gene Using Targeted Deep Sequencing. Blood, 2011, 118, 709-709.	1.4	0
47	Replication of Candidate Gene Single Nucleotide Polymorphisms (SNPs) Previously Reported As Associated with Venous Thromboembolism (VTE). Blood, 2011, 118, 1238-1238.	1.4	0
48	Comparison of characteristics from White- and Black-Americans with venous thromboembolism: A cross sectional study. American Journal of Hematology, 2010, 85, 908-908.	4.1	1
49	ls progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thrombosis Research, 2010, 126, 373-378.	1.7	83
50	Platelet function and relationship to coronary artery disease (CAD) risk in early menopausal women. FASEB Journal, 2010, 24, 589.5.	0.5	0
51	Are Beta-Receptor and Angiotensin-Blocking Drugs Protective Against Venous Thromboembolism (VTE)? A Population Based Case-Control Study. Blood, 2010, 116, 5118-5118.	1.4	0
52	Risk Factors for Venous Thromboembolism (VTE) Among Nursing Home Residents: A Population-Based Case Control Study. Blood, 2010, 116, 476-476.	1.4	1
53	Intra-Abdominal Venous Thrombosis: Characteristics of Pediatric and Adult Patients. Blood, 2010, 116, 4219-4219.	1.4	0
54	Association of Gene-Environment Interactions with Venous Thromboembolism (VTE): A Pathway-Directed Candidate-Gene Case-Control Study. Blood, 2010, 116, 480-480.	1.4	0

Јони А Неіт

#	Article	IF	CITATIONS
55	Is Diabetes Mellitus an Independent Risk Factor for Venous Thromboembolism?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1399-1405.	2.4	101
56	Association of Gene-Gene Interactions with Venous Thromboembolism (VTE): A Pathway-Directed Candidate-Gene Case-Control Study Blood, 2009, 114, 150-150.	1.4	1
57	The Epidemiology of Venous Thromboembolism in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 370-372.	2.4	636
58	Identifying In-Hospital Venous Thromboembolism (VTE). Medical Care, 2008, 46, 127-132.	2.4	41
59	Venous Thromboembolism (VTE) Characteristics among White- and Black-Americans: a Cross Sectional Study. Blood, 2008, 112, 3831-3831.	1.4	1
60	Incidence of Cancer-Associated Venous Thromboembolism (VTE): A Population-Based Cohort Study. Blood, 2008, 112, 3822-3822.	1.4	1
61	Thrombophilia: Common Questions on Laboratory Assessment and Management. Hematology American Society of Hematology Education Program, 2007, 2007, 127-135.	2.5	94
62	Perioperative Outcome of Patients with Acquired Factor X Deficiency Associated with AL Amyloidosis: The Mayo Clinic Experience Blood, 2007, 110, 3965-3965.	1.4	1
63	Risk Factors for Venous Thromboembolism (VTE) among Patients with Active Hematological Cancer: A Population-Based Case-Control Study Blood, 2007, 110, 1642-1642.	1.4	0
64	The Epidemiology of Venous Thromboembolism in the Community: Implications for Prevention and Management. Journal of Thrombosis and Thrombolysis, 2006, 21, 23-29.	2.1	313
65	Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism: A 35-Year Population-Based Study Blood, 2006, 108, 1488-1488.	1.4	18
66	Role of Venous Outflow Obstruction and Venous Valvular Incompetence as Mechanisms for Venous Stasis Syndrome Following Deep Vein Thrombosis: A Population-Based Cohort Study Blood, 2006, 108, 1495-1495.	1.4	2
67	Frequency of Heparin-Induced Thrombocytopenia and Heparin-Dependent IgG Antibodies in Hematopoietic Stem Cell Transplant Recipients Blood, 2006, 108, 4059-4059.	1.4	4
68	Tumor Site and Metastases as Predictors of Venous Thromboembolism Recurrence among Active Cancer Patients with Incident Deep Vein Thrombosis or Pulmonary Embolism: A Population-Based Cohort Study Blood, 2006, 108, 4096-4096.	1.4	0
69	Intensity of Heparin Anticoagulation as an Independent Predictor of 14-Day Recurrence after Deep Vein Thrombosis or Pulmonary Embolism: A Population-Based Cohort Study Blood, 2006, 108, 873-873.	1.4	0
70	Intensity of Warfarin Anticoagulation as an Independent Predictor of 6-Month Recurrence after Deep Vein Thrombosis or Pulmonary Embolism: A Population-Based Cohort Study Blood, 2006, 108, 718-718.	1.4	2
71	Trends in the Incidence of Venous Thromboembolism during Pregnancy or Postpartum: A 30-Year Population-Based Study. Annals of Internal Medicine, 2005, 143, 697.	3.9	1,102
72	Novel Risk Factors for Venous Thromboembolism (VTE): A Population-Based Case-Control Study Blood, 2005, 106, 1618-1618.	1.4	5

Јони А Неіт

#	Article	IF	CITATIONS
73	Estimated Annual Number of US Acute-Care Hospital Inpatients Meeting ACCP Criteria for Venous Thromboembolism (VTE) Prophylaxis Blood, 2005, 106, 903-903.	1.4	8
74	Estimated Annual Number of Incident and Recurrent, Non-Fatal and Fatal Venous Thromboembolism (VTE) Events in the US Blood, 2005, 106, 910-910.	1.4	224
75	Atherosclerosis as a Risk Factor for Venous Thromboembolism (VTE): A Population-Based Cohort Study Blood, 2004, 104, 2584-2584.	1.4	2
76	The Risk of Venous Thromboembolism (VTE) among Cancer Patients by Tumor Site: A Population-Based Study Blood, 2004, 104, 2596-2596.	1.4	4
77	The Seasonal Incidence of Venous Thromboembolism (VTE): A Population-Based Cohort Study Blood, 2004, 104, 3503-3503.	1.4	1
78	The Effect of Patient Age and Calendar Year on the Incidence of Idiopathic vs. Secondary Venous Thromboembolism (VTE): A Population-Based Cohort Study Blood, 2004, 104, 3516-3516.	1.4	2
79	Venous Thromboembolism (VTE) Risk Factors among Nursing Home Residents: A Population-Based Case-Control Study Blood, 2004, 104, 2608-2608.	1.4	2
80	Risk factors for venous thromboembolism. Clinics in Chest Medicine, 2003, 24, 1-12.	2.1	77
81	The Potential Role of Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism. Chest, 2003, 124, 40S-48S.	0.8	21
82	Venous stasis syndrome: the long-term burden of deep vein thrombosis. British Journal of Hospital Medicine, 2003, 64, 593-598.	0.2	6
83	Mapping Out the Future in Venous Thromboembolism and Acute Coronary Syndromes. Seminars in Thrombosis and Hemostasis, 2002, 28, 033-040.	2.7	3
84	Venous Thromboembolism Epidemiology: Implications for Prevention and Management. Seminars in Thrombosis and Hemostasis, 2002, 28, 003-014.	2.7	161
85	Relative Impact of Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 2002, 162, 1245.	3.8	970
86	American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing. Genetics in Medicine, 2001, 3, 139-148.	2.4	166
87	Incidence of Venous Thromboembolism in Hospitalized Patients vs Community Residents. Mayo Clinic Proceedings, 2001, 76, 1102-1110.	3.0	308
88	Current Management of Acute Symptomatic Deep Vein Thrombosis. American Journal of Cardiovascular Drugs, 2001, 1, 45-50.	2.2	3
89	Perioperative management of the chronically anticoagulated patient. Journal of Thrombosis and Thrombolysis, 2001, 12, 81-87.	2.1	87
90	Sensitivity and Specificity of Denaturing High-Pressure Liquid Chromatography for Unknown Protein C Gene Mutations. Genetic Testing and Molecular Biomarkers, 2001, 5, 39-44.	1.7	16

**JOHN A HEIT** 

#	Article	IF	CITATIONS
91	Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement. Annals of Internal Medicine, 2000, 132, 853.	3.9	115
92	Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 2000, 160, 761.	3.8	937
93	Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 2000, 160, 809.	3.8	1,916
94	Predictors of Survival After Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 1999, 159, 445.	3.8	566
95	Determinants of Plasma Fibrin D-Dimer Sensitivity for Acute Pulmonary Embolism as Defined by Pulmonary Angiography. Archives of Pathology and Laboratory Medicine, 1999, 123, 235-240.	2.5	42
96	Germline mutations in Peruvian patients with hemophilia B: Pattern of mutation in AmerIndians is similar to the putative endogenous germline pattern. Human Mutation, 1998, 11, 372-376.	2.5	10
97	Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 1998, 158, 585.	3.8	2,288
98	Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind,	3.4	96

the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind, Dose-ranging Study. Thrombosis and Haemostasis, 1997, 77, 032-038. 98